Nov 16, 2017 — Dr. Watts has held a number of clinical and administrative leadership positions at two renowned academic medical centers, Northwestern (Feinberg School of Medicine, Northwestern Memorial Hospital) and the University of Michigan, and with his training and extensive clinical career as a Pulmonary-Critical Care specialist, he adds a comprehensive background of clinical practice and healthcare administration to […]
New from LabRoots: Dr. Margie Morgan to present on the impact of fast phenotypic susceptibility results to laboratory workflow and patient outcomes
Nov 09, 2017 — Dr. Margie Morgan, Scientific Director Microbiology at Cedars-Sinai Medical Center, is scheduled to present on the impact that fast phenotypic antibiotic susceptibility results have to laboratory workflow and patient outcomes at the LabRoots Clinical Diagnostics and Research Virtual Event, November 9th at 12:30 p.m. ET.
Accelerate Diagnostics reports Q3 2017 financial results
Nov 02, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending September 30, 2017. The company further reported signed agreements for 295 instruments year to date; contracts for customer evaluations total 239 instruments while revenue generating placements grew to 56 across the U.S., European, and Middle East regions.
Third Quarter 2017 Conference Call Set for November 2nd
Oct 17, 2017 — Accelerate Diagnostics, Inc. will announce third quarter 2017 financial results at the close of U.S. financial markets on Thursday, November 2, 2017.
See all news
Enter your email address below for access to photos, logos and videos.
Connect with us
February 25-28, 2018
San Antonio, TX
December 18-19, 2017
Palais des Congrès de Paris
Stay up to date with Accelerate by joining our mailing list.Sign up today
October 4–8, 2017
June 1–5, 2017
May 10–13, 2017
Friday, May 5, 2017
April 22–25, 2017
March 26–28, 2017
Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.